DK2477980T3 - Hcv-proteaseinhibitorer - Google Patents
Hcv-proteaseinhibitorer Download PDFInfo
- Publication number
- DK2477980T3 DK2477980T3 DK09849606.0T DK09849606T DK2477980T3 DK 2477980 T3 DK2477980 T3 DK 2477980T3 DK 09849606 T DK09849606 T DK 09849606T DK 2477980 T3 DK2477980 T3 DK 2477980T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- heteroaryl
- aryl
- heterocycloalkyl
- cdci3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (14)
1. Forbindelse med den følgende formel:
hvor Ri er -H, -OH, Ci-β alkyl, Ci-e alkoxyl, C3-10 cycloalkyl, C1-10 heterocycloalkyl, aryl, heteroaryl, eller -NH-Z-R; hvor R er H, eller er en del valgt fra Ci-s alkyl, C3-10 cycloalkyl, Ci-io heterocycloalkyl, a ry i, og heteroaryl, der hver eventuel er mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, C1-6 alkyl, C1-6 alkoxyl, C2-6 alkenyl, C2-6 alkynyl, aryl, eller heteroaryl; og Z er -C(O)-, -C(0)0-, -C(0)C(0)0-, -C(0)C(0)NH-, -C(0)NR'-, -OC(S)-, -C(S)NR'-, eller -C(NH)0-, R! er H, Ci-e alkyl, €3-10 cycloalkyl, C1-10 heterocycloalkyl, aryl, eller heteroaryl; R2 er H, eller er en del valgt fra Ci-s a I kyl, C3-10 cycloalkyl, C1-10 heterocycloalkyl, aryl, og heteroaryl, der hver eventuel er mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, Ci-s alkyl, Ci-s alkoxyl, C2-6 alkenyl, C2-6 alkynyl, aryl, eller heteroaryl; A er N eller CH; U er -O-, ~NH-, -NH(CO)-, -NHSO-, eller -NHSO2-; W er -(CH2)m-, -NH(CH2)n-, -(CH2)nNH-, -0(CH2)n-, -(CH2)nO-, -S(CH2)n-, -{CH2)nS-, -SO-, -SO(CH2)n-, -(CH2)nSO-, -S02(CH2)n-, eller -(CH2)nS02-, m er 1, 2, eller 3 og n er 0, i, eller 2; X er -O-, -S-, eller -NH-; og Y er
eiier
* hvor hver af V og T, uafhængigt, er -CH- eller -N-; hver af Ai og A2, uafhængigt, er en del valgt fra C4-10 cycloalkyl, C1-10 heterocycloalkyl, aryl, og heteroaryl, der hver eventuel er mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, Ci-β alkyl, C1-6 alkoxyl, C2-6 alkenyl, C2-6 alkynyi, aryl, eller heteroaryl, eller eventuelt fusioneret med C3-10 cycloalkyl, C2-10 heterocycloalkyl, aryl, eller heteroaryl; og Ri er H, halo, nitro, cyano, eller amino, eller er en del valgt fra C1-6 alkyl, Q-s alkoxyl, C2-S alkenyl, C2-S alkynyi, C3-1.0 cycloalkyl, C1-10 heterocycloalkyl, aryl, og heteroaryl, hver af C i-6 alkyl, C1-6 alkoxyl, C2-5 alkenyl, og C2-6 alkynyi er eventuelt mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, Q-e alkyl, Ci-e alkoxyl, C2-6 alkenyl, C2-6 alkynyi, Cs-io cycloalkyl, C1-10 heterocycloalkyl, aryl, eller heteroaryl, og hver af C3-10 cycloalkyl, C1-10 heterocycloalkyl, aryl, og heteroaryl er eventuelt mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, C1.-5 alkyl, C1-6 alkoxyl, C2-6 alkenyl, C2-6 alkynyi, C3 :o cycloalkyl, C1-10 heterocycloalkyl, aryl, eller heteroaryl, eller eventuelt fusioneret med C3-1G cycloalkyl, C1-10 heterocycloalkyl, aryl, eller heteroaryl.
2. Forbindelsen ifølge krav 1, hvor A er CH og W er -CH2CH2-, -OCH2-, -SCH2-, eller -SOCH2-.
3. Forbindelse med følgende formel:
hvor Ri er -H, -OH, Ci-s alkyl, Ci-s alkoxyl, C3-10 cycloalkyl, Cmq heterocycloalkyl, aryl, heteroaryl, eller -Z-R; hvor R er H, eller er en del valgt fra Ci-e alkyl, C3-10 cycloalkyl, C1-10 heterocycloalkyl, aryl, og heteroaryl, der hver eventuel er mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, Ci-s alkyl, Ci-e alkoxyl, C2-6 alkenyl, C2-6 alkynyl, aryl, eller heteroaryl; og Z er -0(0)-, -0(0)0-, -0(0)0(0)0-, -0(0)0(0)NH-, -C(0)NR'-, -OC(S)-, - C(S)NR'-, eller -C(NH)0-, R' er H,Ci-e alkyl, C3-10 cycloalkyl, Ci 10 heterocycloalkyl, aryl, eller heteroaryl, Rz er H, eller er en del valgt fra Ci-s alkyl, C3-10 cycloalkyl, C1-10 heterocycloalkyl, aryl, og heteroaryl, der hver eventuel er mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, Ci-e alkyl, Ci-e alkoxyl, C2-6 alkenyl, C2-6 alkynyl, aryl, eller heteroaryl; A er OH eller N; U er -O-, -NH-, -NH(CO)-, -NHSO-, eller -NHSO2-; W er -(CH2)m-, -NH(CHz)n-, -(CH2)nNH-, -0(CH2)n-, -(CH2)nO-, -S(CH2)n-, -(CH2)nS-, -SO-, -SO(CH2)n-, -(CH2)nSO-, -S02(CH2)n-, eller -(CH2)nS02-, m er 1, 2, eller 3 og n er O, 1, eller 2; X er -O-, -S-, eller -NH-; Y er
eller
hvor hver af V og T, uafhængigt, er -CH- eller -N-; hver af Ai og Az, uafhængigt, er en del valgt fra C4-10 cycloalkyl, C2-io heterocycloalkyl, aryl, og heteroaryl, der hver eventuel er mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, Ci-e alkyl, Ci-e alkoxyl, C2-6 alkenyl, C2-6 alkynyl, aryl, eller heteroaryl, eller eventuelt fusioneret med C3-10 cycloalkyl, Cmq heterocycloalkyl, aryl, elier heteroaryl; og Ri er H, halo, nitro, cyano, eller amino, eller er en del valgt fra Ci-e alkyl, Ci-s alkoxyl, C2-s alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C1-10 heterocycloalkyl, aryl, og heteroaryl, hver af C1-5 alkyl, Ci-β alkoxyl, C2-6 alkenyl, og C2-6 alkynyl er eventuelt mono-, di-,or tri-substitueret med halo, nitro, cyano, amino, Ci-β alkyl, Ci-e alkoxyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C1-10 heterocycloalkyl, aryl, eller heteroaryl, og hver af C3-10 cycloalkyi, C1-10 heterocycloalkyl, aryl, og heteroaryl er eventuelt mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, Ci-e alkyl, Ci-s alkoxyl, C2-6 alkenyl, C2-6 alkynyl, C3-io cycloalkyl, Ci-10 heterocycloalkyl, aryl, eller heteroaryl, eller eventuelt fusioneret med C3-10 cycloalkyi, Ci-10 heterocycloalkyl, aryl, eller heteroaryl; og
er en enkeltbinding eller en dobbeltbinding.
4. Forbindelsen ifølge krav 3, hvor W er -CH2CH2-, -OCH2-, -SCH2-, or-SOCH2-; og
er en dobbeltbinding.
5. Forbindelse med følgende formel:
>hvor Ri er -H, -OH, Ci-6 alkyl, C1-5 alkoxyl, C3-10 cycloalkyi, Ci-lo heterocycloalkyl, aryl, heteroaryl, -Z-R, eller -NH-Z-R; hvor R er H, eller er en del valgt fra Ci-e alkyl, C3-10 cycloalkyi, Ci-10 heterocycloalkyl, aryl, og heteroaryl, der hver eventuel er mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, Ci-s alkyl, Ci-β alkoxyl, C2-6 alkenyl, C2-6 alkynyl, aryl, eller heteroaryl; og Z er -C(O)-, -C(0)0-, -C(0)C(0)0-, -C(0)C(0)NH-, -C(0)IMR'-, -OC(S)-, - C(S)NR-, eller -C(NH)0-, R' er H, Ci-s alkyl, C3-io cycloalkyi, Ci-10 heterocycloalkyl, aryl, eller heteroaryl; A er N eller CH; U er -O-, -NH-, -NH(CO)-, -NHSO-, eller -NHSO2-; Wer-(CH2)n-, -NH(CH2)n-, -(CH2)„NH-, -0(CH2)n-, -(CH2)nO-, -S(CH2)n-, -(CH2)nS-, -SO-, -SO(CH2)„-, -(CH2)nSO-, -S02(CH2)n-, eller -(CH2)nS02-, m er 1, 2, eller 3 og n er 0, 1, eller 2; X er -O-, -S-, eller -NH-; Y er
eller
hvor hver af V og T, uafhængigt, er -CH- eller -N-; hver af Ai og A2, uafhængigt, er en del valgt fra C4-10 cydoalkyi, C2-10 heterocycloalkyl, aryl, og heteroaryl, der hver eventuel er mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, Ci-e alkyl, C1-6 alkoxyl, C2-e alkenyl, C2-s alkynyl, aryl, eller heteroaryl, eller eventuelt fusioneret med G3-10 cydoalkyi, C1-10 heterocycloalkyl, aryl, eller heteroaryl; og Ri er H, halo, nitro, cyano, eller amino, eller er en del valgt fra C1-6 alkyl, C1-6 alkoxyl, Q-s alkenyl, C2-6 alkynyl, C3-.10 cydoalkyi, Ci-io heterocycloalkyl, aryl, og heteroaryl, hver af C1.-6 alkyl, C1-6 alkoxyl, C2-6 alkenyl, og C2-s alkynyl er eventuelt mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, Ci-s alkyl, Ci-e alkoxyl, Cz-s alkenyl, Q-s alkynyl, C3-10 cydoalkyi, C1-10 heterocycloalkyl, aryl, eller heteroaryl, og hver af C3-10 cycloalkyl, C1-10 heterocycloalkyl, aryl, og heteroaryl er eventuelt mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, Ci-s alkyl, Ci-s alkoxyl, Cz-β alkenyl, C2-s alkynyl, C3-10 cycloalkyl, C1-10 heterocycloalkyl, aryl, eller heteroaryi, eller eventuelt fusioneret med C3-10 cydoalkyi, Ct ic heterocycloalkyl, aryl, eller heteroaryl; og
er en enkeltbinding eller en dobbeltbinding.
6. Forbindelsen ifølge krav 5, hvor A er CH; W er -CH2CH2-, -OCH2-, -SCH2-, eller -SOCH2-; og
er en dobbeltbinding.
7. Forbindelsen ifølge et hvilket som helst af kravene 1 til 6, hvor X er O.
8. Forbindelsen ifølge et hvilket som helst af kravene 1 til 7, hvor U er -NHSO2-.
9. Forbindelsen ifølge et hvilket som helst af kravene 1 til 8, hvor Y er
hvor T er CH eller N og hver af Ri, Ru, Rin, Riv, og Rv, uafhængigt, er H, halo, nitro, cyano, amino, Ci-e alkyl, Ci-s alkoxyl, C2-6 alkenyl, eller C2 6 alkynyl, eller er en del valgt fra Cs-io cycloalkyl, C1-10 heterocycloalkyl, aryl, og heteroaryl, der hver eventuel er mono-, di-, eller tri-substitueret med halo, nitro, cyano, amino, Ci-e alkyl, Ci-6 alkoxyl, C2-6 alkenyl, C2-6 alkynyl, aryl, eller heteroaryl, eller eventuelt fusioneret med C3-10 cycloalkyl, C1-10 heterocycloalkyl, aryl, eller heteroaryl.
10. Forbindelse, hvor forbindelsen er én af følgende forbindelser:
II. Forbindelse, hvor forbindelsen er én af følgende forbindelser:
12. Farmaceutisk sammensætning omfattende en forbindelse ifølge e*. hvilket som helst af kravene 1-11 og en farmaceutisk acceptabel bærer.
13. Forbindelse ifølge et hvilket som helst af kravene 1-11 til anvendelse i behandling af hepatitis C virusinfektion.
14. Forbindelse ifølge krav 13 til anvendelse i behandling af hepatitis C virusinfektion, hvor forbindelsen skal administreres oralt til et individ med behov for behandlingen.
15. Forbindelse ifølge krav 13 eller 14 til anvendelse i behandling af hepatitis C virusinfektion, hvor forbindelsen skal administreres én gang daglig.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2009/056937 WO2011034518A1 (en) | 2009-09-15 | 2009-09-15 | Hcv protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2477980T3 true DK2477980T3 (da) | 2016-09-12 |
Family
ID=43758907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09849606.0T DK2477980T3 (da) | 2009-09-15 | 2009-09-15 | Hcv-proteaseinhibitorer |
Country Status (21)
Country | Link |
---|---|
US (1) | US8389560B2 (da) |
EP (1) | EP2477980B1 (da) |
JP (1) | JP5702388B2 (da) |
KR (1) | KR101670319B1 (da) |
AU (1) | AU2009352688B2 (da) |
CA (1) | CA2774145C (da) |
CY (1) | CY1118136T1 (da) |
DK (1) | DK2477980T3 (da) |
EA (1) | EA022118B1 (da) |
ES (1) | ES2588204T3 (da) |
HR (1) | HRP20161025T1 (da) |
HU (1) | HUE030402T2 (da) |
LT (1) | LT2477980T (da) |
NZ (1) | NZ599133A (da) |
PL (1) | PL2477980T3 (da) |
PT (1) | PT2477980T (da) |
SG (1) | SG179566A1 (da) |
SI (1) | SI2477980T1 (da) |
SM (1) | SMT201600291B (da) |
WO (1) | WO2011034518A1 (da) |
ZA (1) | ZA201202631B (da) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
EA201170441A1 (ru) * | 2008-10-15 | 2012-05-30 | Интермьюн, Инк. | Терапевтические противовирусные пептиды |
CA2775697A1 (en) * | 2009-09-28 | 2011-03-31 | Intermune, Inc. | Cyclic peptide inhibitors of hepatitis c virus replication |
TW201116540A (en) * | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
US20110178107A1 (en) * | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
AU2011352145A1 (en) | 2010-12-30 | 2013-07-18 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
MX2013007677A (es) | 2010-12-30 | 2013-07-30 | Abbvie Inc | Inhibidores macrociclicos de serina proteasa de hepatitis. |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
CN102911254A (zh) * | 2011-08-02 | 2013-02-06 | 上海唐润医药科技有限公司 | Hcv蛋白酶抑制剂 |
MX355102B (es) | 2012-01-11 | 2018-04-05 | Abbvie Ireland Unlimited Co | Procesos para hacer los inhibidores de la proteasa del hcv. |
TWI623539B (zh) | 2012-09-20 | 2018-05-11 | Udc愛爾蘭責任有限公司 | 供電子應用之氮雜二苯并呋喃 |
CN104822682A (zh) | 2012-10-08 | 2015-08-05 | 艾伯维公司 | 用于制备hcv蛋白酶抑制剂的化合物 |
MX360452B (es) | 2012-10-19 | 2018-11-01 | Bristol Myers Squibb Co | Inhibidores del virus de la hepatitis c. |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CN104557954A (zh) * | 2013-10-16 | 2015-04-29 | 上海唐润医药科技有限公司 | 抗hcv的大环化合物 |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
CN104447952A (zh) * | 2014-12-11 | 2015-03-25 | 上海唐润医药科技有限公司 | 丙肝病毒蛋白酶抑制剂及其合成方法 |
CN108727417B (zh) * | 2015-02-05 | 2021-10-08 | 爱博新药研发(上海)有限公司 | 多环化合物钠盐及其多晶型、制备方法及应用 |
US11691983B2 (en) | 2016-06-22 | 2023-07-04 | Idemitsu Kosan Co., Ltd. | Specifically substituted benzofuro- and benzothienoquinolines for organic light emitting diodes |
WO2018222172A1 (en) * | 2017-05-30 | 2018-12-06 | Taigen Biotechnology Co., Ltd. | Solid dispersion formulation |
US10004719B1 (en) | 2017-05-30 | 2018-06-26 | Taigen Biotechnology Co., Ltd. | Solid dispersion formulation |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4555508A (en) * | 1984-03-02 | 1985-11-26 | Usv Pharmaceutical Corp. | Antihypertensive spiro-cyclic compounds |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
AU2933797A (en) | 1996-05-10 | 1997-12-05 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
US5876984A (en) * | 1996-09-25 | 1999-03-02 | Shionogi & Co., Ltd | Sequiterpene derivatives having antiviral activity |
JP4080541B2 (ja) | 1996-10-18 | 2008-04-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子 |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
ES2281170T3 (es) | 1998-03-31 | 2007-09-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c. |
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US20030073618A1 (en) | 2001-02-08 | 2003-04-17 | Kozhemyakin Leonid A. | Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof |
US20020182647A1 (en) | 2001-04-30 | 2002-12-05 | Emmert-Buck Michael R. | Histoscreen method |
ATE349463T1 (de) * | 2001-07-11 | 2007-01-15 | Vertex Pharma | Verbrückte bizyklische serinproteaseinhibitoren |
US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
PE20030857A1 (es) * | 2002-01-23 | 2003-10-25 | Schering Corp | Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c |
US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
NZ561851A (en) | 2002-04-11 | 2009-05-31 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease |
MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
ES2315568T3 (es) * | 2002-05-20 | 2009-04-01 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido. |
US7601367B2 (en) | 2002-05-28 | 2009-10-13 | Mirus Bio Llc | Compositions and processes using siRNA, amphipathic compounds and polycations |
BR0315897A (pt) | 2002-11-01 | 2008-05-13 | Abbott Lab | agentes antiinfecciosos |
KR100940619B1 (ko) | 2003-02-07 | 2010-02-05 | 이난타 파마슈티칼스, 인코포레이티드 | 마크로사이클릭 씨형 간염 세린 단백효소 억제제 |
TW200510391A (en) | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
CA2521678A1 (en) | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals, Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
ATE422895T1 (de) | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
CA2528597C (en) | 2003-06-11 | 2014-08-05 | Hybridon, Inc. | Stabilized immunomodulatory oligonucleotides |
EP1646642A2 (en) | 2003-07-18 | 2006-04-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
EP1664091A1 (en) | 2003-09-18 | 2006-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
DE602004031645D1 (de) | 2003-09-22 | 2011-04-14 | Boehringer Ingelheim Pharma | Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus |
KR20060085248A (ko) * | 2003-09-26 | 2006-07-26 | 쉐링 코포레이션 | C형 간염 바이러스 ns3 세린 프로테아제의마크로사이클릭 억제제 |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
EP1689770A1 (en) * | 2003-11-20 | 2006-08-16 | Schering Corporation | Depeptidized inhibitors of hepatitis c virus ns3 protease |
AU2004298498B2 (en) * | 2003-12-11 | 2008-09-11 | Schering Corporation | Inhibitors of hepatitis C virus NS3/NS4a serine protease |
CA2549851C (en) | 2004-01-21 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
JP2008513454A (ja) * | 2004-09-17 | 2008-05-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大環状hcvプロテアーゼインヒビターの調製方法 |
US20070207949A1 (en) * | 2005-06-02 | 2007-09-06 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
WO2006130607A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
UY30437A1 (es) | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c |
US7605126B2 (en) * | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
WO2008022006A2 (en) * | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis c virus protease inhibitors |
US20080267917A1 (en) * | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
WO2008134395A1 (en) * | 2007-04-26 | 2008-11-06 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis c serine protease inhibitors |
US20090005387A1 (en) * | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
WO2009055335A2 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
-
2009
- 2009-09-15 US US12/559,818 patent/US8389560B2/en active Active
- 2009-09-15 NZ NZ599133A patent/NZ599133A/xx not_active IP Right Cessation
- 2009-09-15 EP EP09849606.0A patent/EP2477980B1/en active Active
- 2009-09-15 PL PL09849606T patent/PL2477980T3/pl unknown
- 2009-09-15 WO PCT/US2009/056937 patent/WO2011034518A1/en active Application Filing
- 2009-09-15 EA EA201270423A patent/EA022118B1/ru unknown
- 2009-09-15 PT PT98496060T patent/PT2477980T/pt unknown
- 2009-09-15 DK DK09849606.0T patent/DK2477980T3/da active
- 2009-09-15 CA CA2774145A patent/CA2774145C/en not_active Expired - Fee Related
- 2009-09-15 LT LTEP09849606.0T patent/LT2477980T/lt unknown
- 2009-09-15 ES ES09849606.0T patent/ES2588204T3/es active Active
- 2009-09-15 SG SG2012018412A patent/SG179566A1/en unknown
- 2009-09-15 KR KR1020127009259A patent/KR101670319B1/ko active IP Right Grant
- 2009-09-15 SI SI200931505A patent/SI2477980T1/sl unknown
- 2009-09-15 HU HUE09849606A patent/HUE030402T2/en unknown
- 2009-09-15 JP JP2012529723A patent/JP5702388B2/ja not_active Expired - Fee Related
- 2009-09-15 AU AU2009352688A patent/AU2009352688B2/en not_active Ceased
-
2012
- 2012-04-12 ZA ZA2012/02631A patent/ZA201202631B/en unknown
-
2016
- 2016-08-16 HR HRP20161025TT patent/HRP20161025T1/hr unknown
- 2016-08-29 SM SM201600291T patent/SMT201600291B/it unknown
- 2016-08-31 CY CY20161100856T patent/CY1118136T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US20110065737A1 (en) | 2011-03-17 |
NZ599133A (en) | 2013-10-25 |
LT2477980T (lt) | 2016-09-26 |
SI2477980T1 (sl) | 2017-01-31 |
JP5702388B2 (ja) | 2015-04-15 |
AU2009352688A1 (en) | 2012-04-26 |
EP2477980A4 (en) | 2013-05-01 |
ZA201202631B (en) | 2012-12-27 |
CY1118136T1 (el) | 2017-06-28 |
PT2477980T (pt) | 2016-08-31 |
EP2477980B1 (en) | 2016-06-08 |
SG179566A1 (en) | 2012-05-30 |
HRP20161025T1 (hr) | 2016-11-04 |
EA022118B1 (ru) | 2015-11-30 |
KR20120110091A (ko) | 2012-10-09 |
SMT201600291B (it) | 2016-11-10 |
JP2013504616A (ja) | 2013-02-07 |
ES2588204T3 (es) | 2016-10-31 |
KR101670319B1 (ko) | 2016-10-28 |
HUE030402T2 (en) | 2017-05-29 |
CA2774145A1 (en) | 2011-03-24 |
AU2009352688B2 (en) | 2014-04-17 |
US8389560B2 (en) | 2013-03-05 |
CA2774145C (en) | 2015-10-27 |
WO2011034518A1 (en) | 2011-03-24 |
EA201270423A1 (ru) | 2012-09-28 |
EP2477980A1 (en) | 2012-07-25 |
PL2477980T3 (pl) | 2017-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2477980T3 (da) | Hcv-proteaseinhibitorer | |
DK2274281T3 (da) | Hcv-proteaseinhibitorer | |
EP2528922B1 (en) | Polyheterocyclic compounds as hcv inhibitors | |
US6608027B1 (en) | Macrocyclic peptides active against the hepatitis C virus | |
AU778390B2 (en) | Macrocyclic peptides active against the hepatitis C virus | |
US20090111757A1 (en) | Hcv protease inhibitors | |
US20080207528A1 (en) | Hcv protease inhibitors | |
US20110178107A1 (en) | Hcv protease inhibitors | |
TW201211046A (en) | Macrocyclic hepatitis C serine protease inhibitors | |
US8962810B2 (en) | Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof | |
CN102020698B (zh) | 丙型肝炎病毒蛋白酶抑制剂 | |
TWI429450B (zh) | 丙型肝炎病毒蛋白酶抑制劑 |